Ivonescimab a PD-1/VEGF bispecific shows 65.2% ORR in untreated IMDC favorable-risk RCC at #ESMO26. CheckMate 9ER's favorable-risk ORR was 66.2% with nivo/cabo.

🎯 Ivonescimab phase Ib/II, 23 evaluable: DCR 95.7%, 12-month PFS 85.5%, no deaths
⚠️ Grade 3-4 TRAEs 26.9%, proteinuria 15.4%
📐 Cross-trial, single arm, 13 months of follow-up. Hypothesis-generating.
#ESMO26 #KidneyCancer #RCC #GUonc @myESMO